Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy

Toxicology Letters

Volumn 146, Issue 3, 2004, Pages 275-284

  Vranić Mandušić, Vesna ^a   Subota, Vesna ^b   Savovski, Kiril ^a   Medić, Ljubica ^c   Dramićanin, Tatjana ^a   Jozanov Stankov, Olga ^a   Popov Čeleketić, Dušan ^a   Jokanović, Milan ^d   Dimitrijević, Bogomir ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

^c ICN   (Yugoslavia)

^d Research and Development Institute

Author keywords

Aberrant morphology; Erythrocytotoxicity; Hemolysis; Scanning probe microscopy; Tiazofurin

Indexed keywords

BUFFER; TIAZOFURIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SMEAR; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE STRUCTURE; FLOW CYTOMETRY; HEMOLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SCANNING PROBE MICROSCOPY;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0346366558     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.10.013     Document Type: Article

References (25)

1. Aeibi H. Catalase in vitro. Methods Enzymol. 105:1984;121-126.
2. Ahluwalia S., Jayaram H.N., Plowman J.P., Cooney D.A., Jones D.J. Studies of the mechanism of action of 2-β-D-ribofuranosylthiazole-4- carboxamide-V. Factors governing the response of murine tumors to tiazofurinm. Biochem. Pharmacol. 33:1984;1195-1203.
3. Balducci L., Hardy C.L. Advanced lewis lung carcinoma cured by tiazofurin as a system to study delayed hemopoietic effects of cancer. Cancer Invest. 6(6):1988;681-686.
4. Francheti P., Grifantini M. Nucleoside and non-nucleoside IMPDH inhibitors as antitumor and antiviral agents. Curr. Med. Chem. 6:1999;599-614.
5. Goldstein B.M., Leary J.F., Farley B.A., Marqez V.E., Levy P.C., Rowley P.T. Induction of HL 60 cell differentiation by tiazofurin and its analogues: characterization and efficacy. Blood. 78(3):1991;593-598.
6. Green R.M., Stewart D.J., Maroun J.A. Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286 193). Invest. New Drugs. 4:1986;387-394.
7. Grem J.L., Rubinstein L., King S.A., Cheson B.D., Hawkins M.J., Shoemaker D.D. Clinical toxicity associated with tiazofurin. Invest. New Drugs. 8:1990;227-238.
8. Hata Y., Natsumeda Y., Weber G. Tiazofurin decreases Ras-GTP complex in K562 cells. Oncol. Res. 5:1993;161-164.
9. Jayaram H.N., Pillwein K., Nichols C.R., Hoffman R., Weber G. Selective sensitivity to tiazofurin of human leukemic cells. Biochem. Pharmacol. 35:1986;2029-2032.
10. Jayaram H.N., Lapis E., Tricot J., Kneebone P., Paulik E., Zhen W., Engeler G.P., Hoffman R., Weber G. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. Int. J. Cancer. 51(2):1992;182-188.
11. Lapis K., Bocsi J., Tóvári J., Bartha I., Timár J., Rásó E. Antiinvasive effects of tiazofurin on liver-metastatic human colon carcinoma xenografts. Anticancer Res. 16:1996;3323-3332.
12. Melink J.T., Von Hoff D.D., Kuhn J.G., Hersh M.R., Sternson L.A., Patton F.T., Siegler R., Boldt D.H., Clark G.M. Phase I evaluation and pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res. 45:1985;859-865.
13. Milutinović, D., 1985. Tiazofurin acute parenteral (i.p.) toxicity in rats. ICN GALENIKA, Belgrade (Research report).
14. Monks A., Marquez V.R., Mao D.T., Cysyk R.L. Uptake of 2-β-D-ribofuranosylthiazole-4-carboxamide-(tiazofurin) and analogues by the facilitated transport mechanism of erythrocytes. Cancer Lett. 28:1985;1-8.
15. Nagai M., Natsumeda J., Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res. 52:1992;258-261.
16. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70(1):1967;158-169.
17. Rásó E., Lapis K. Inhibition of progression of human and rat Wilm's tumor by tiazofurin. Anticancer Res. 16:1996;3333-3340.
18. Roberts J.D., Tong W.P., Hartshorn J.N., Hacker M.P. Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro. Cancer Lett. 32(2):1986;193-197.
19. Roberts J.D., Stewart J.A., McCormack J.J., Krakoff I.R., Culham C.A., Hartshorn J.N., Newman R.A., Haugh L.D., Jung J.A. Phase I trial of tiazofurin administered by IV bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat. Rep. 71(2):1987;141-149.
20. Satoh K. Improvement of the thiobarbituric acid method for malondialdehyde determination. Clin. Chim. Acta. 90:1978;37-43.
21. Tóvári J., Bocsi J., Ladányi A., Lapis K., Timár J. The antitumor effect of tiazofurin (TR) consist of anti-proliferative and anti-invasive elements. Anticancer Res. 16:1996;3307-3312.
22. Tricot G., Weber G. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Anticancer Res. 16:1996;3341-3348.
23. Trump D.L., Tutsch K.D., Koeller J.M., Tormey D.C. Phase I clinical study with pharmacokinetic analysis 2-β-D-ribofuranosylthiazole-4- carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res. 45:1985;2853-2858.
24. Uchiyama M., Michara M. Determination of malondialdehyde precursors in tissues by thiobarbituric acid test. Anal. Biochem. 86:1978;271-278.
25. Vranić, V., Savovski, K., Dedovic, N., Dimitrijevic, B., 2000. Hematological toxicity associated with tiazofurin - influence on erythropoiesis, Toxicol. Lett. 114, 81-90.